Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib + Doxorubicin in Solid Tumors and SCLC
NCT02261805Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Oct 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ganetespib in small cell lung cancer (SCLC) and solid tumor (3 arms), sponsored by Georgetown University. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Oct 2014; status: terminated.
02
Drugs
ganetespib
03
Conditions
small cell lung cancer (SCLC)solid tumor
Beyond the preview
Go deeper on NCT02261805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261805.